Company intelligence / Profile preview

MRM Health

Ownership: Private
Employees: ~33
Development stage: Other

Overview

MRM Health has demonstrated positive Phase 2a results for its lead live biotherapeutic consortium MH002 in ulcerative colitis and pouchitis. The company’s proprietary CORAL® technology enables the design and scalable manufacturing of optimized microbial consortia as single drug substances. Additional programs are advancing through preclinical development targeting immuno-oncology, autoimmune disorders, metabolic dysfunction-associated steatotic liver disease (MASH), spondylarthritis, and Parkinson’s disease.

Therapeutic areas: GastroenterologyRheumatologyImmunologyNeurology
Modalities: Live biotherapeutic product therapyMicrobial therapy
Industry: Biotech

Drug pipeline

1 asset

MH002

Partnerships

IFF/DuPont Nutrition BiosciencesVIBEvonik

Beyond the preview

Go deeper on MRM Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRM Health.

Explore the full profile